RT Journal Article
SR Electronic
T1 Combined adenine nucleotide translocator 2 (ANT2) shRNA therapy and hNIS radionuclide gene therapy in mouse model of colon cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1580
OP 1580
VO 50
IS supplement 2
A1 Young-Hwa Kim
A1 Yong Hyun  Jeon
A1 Yun  Choi
A1 Hyewon  Youn
A1 Keon Wook Kang
A1 Jae Min  Jeong
A1 Dong Soo Lee
A1 Chul Woo  Kim
A1 JK Chung
YR 2009
UL http://jnm.snmjournals.org/content/50/supplement_2/1580.abstract
AB 1580 Objectives Recently, we reported on the anti-tumor effects of vector-based ANT2 shRNA therapy in human breast cancer model. In this study, we investigated the therapeutic effects of combined ANT2 shRNA therapy and hNIS radionuclide gene therapy in mouse colon cancer cells. Methods Mouse colon cancer cells expressing hNIS (CT26/hNIS) were treated with HBSS, ANT2 scramble vector (AS), ANT2 shRNA vector (AR), I-131, ANT2 scramble vector + I-131 (ASI), and ANT2 shRNA vector + I-131 (ARI) using Lipofectamine 2000 and I-131 (300 uCi/5 mL). Twenty-four hours later, apoptotic cell death rates (%), I-125 uptake, and the levels of MHC class I and Fas gene expression were measured in various groups of CT26/hNIS cells using a gamma counter and FACS analysis. Results The rates of apoptotic cell death were 0.1, 0.1, 22.1, 14, 10.5, 43.1% in HBSS, AS, AR, I-131, ASI, and ARI group, respectively. ARI group showed the least uptake of I-125 among six groups. The levels of MHC class I expressing cancer cells were 11.9, 12.7, 17.6, 59.3, 58, and 75% in HBSS, AS, AR, I-131, ASI, and ARI group, respectively. The percentage of Fas expressing cancer cells were 5.7, 6.8, 20.6, 17.9, 16.8, and 49.9% in HBSS, AS, AR, I-131, ASI, and ARI group, respectively. Conclusions Our data suggest that combined vector-based ANT2 shRNA therapy and hNIS radionuclide gene therapy could be an effective therapeutic method for cancer treatment.